PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+19.43%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.97B
AUM Growth
+$2.97B
(-14%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
46.1%
Holding
105
New
9
Increased
22
Reduced
25
Closed
10
Top Buys
| 1 |
Immunovant
IMVT
|
$49.6M |
| 2 |
argenx
ARGX
|
$40.1M |
| 3 |
Apogee Therapeutics
APGE
|
$38.9M |
| 4 |
Revolution Medicines
RVMD
|
$36.6M |
| 5 |
Tango Therapeutics
TNGX
|
$27.2M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$74M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$68.3M |
| 3 |
Vir Biotechnology
VIR
|
$48M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$40M |
| 5 |
Illumina
ILMN
|
$27.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amicus Therapeutics
FOLD
$2.34B
| $337M | 11.23% | 27,692,917 +30,000 | +0.1% | +$365K |
|
|
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $220M | 7.35% | 10,088,385 | – | – |
|
|
3
Immunovant
IMVT
$2.56B
| $146M | 4.88% | 3,814,691 +1,290,908 | +51% | +$49.6M |
|
4
Arcellx
ACLX
$3.85B
| $142M | 4.75% | 3,965,978 -50,419 | -1% | -$1.81M |
|
5
Nuvalent
NUVL
$5.52B
| $113M | 3.78% | 2,463,451 +268,630 | +12% | +$12.3M |
|
6
Soleno Therapeutics
SLNO
$3.6B
| $90.7M | 3.03% | 3,074,542 +866,789 | +39% | +$25.6M |
|
|
LIAN
7
DELISTED
LianBio American Depositary Shares
LIAN
| $85.8M | 2.86% | 57,558,451 | – | – |
|
8
Akero Therapeutics
AKRO
$3.74B
| $81.9M | 2.73% | 1,619,425 -321,250 | -17% | -$16.2M |
|
|
INBX
9
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $78.1M | 2.61% | 4,256,104 +631,922 | +17% | +$11.6M |
|
10
Aldeyra Therapeutics
ALDX
$351M
| $75.8M | 2.53% | 11,350,085 | – | – |
|
|
11
argenx
ARGX
$43.6B
| $74M | 2.47% | 150,600 +81,600 | +118% | +$40.1M |
|
12
Vaxcyte
PCVX
$4B
| $68.5M | 2.28% | 1,342,751 -271,371 | -17% | -$13.8M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $65.3M | 2.18% | 4,007,197 -389,919 | -9% | -$6.36M |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $60.3M | 2.01% | 4,043,191 +309,936 | +8% | +$4.62M |
|
15
MeiraGTx Holdings
MGTX
$587M
| $55.6M | 1.86% | 11,331,103 | – | – |
|
16
Iovance Biotherapeutics
IOVA
$807M
| $54.4M | 1.82% | 11,962,938 -2,073,472 | -15% | -$9.43M |
|
17
Lyra Therapeutics
LYRA
$11.5M
| $49.9M | 1.66% | 12,757,562 | – | – |
|
|
18
Amylyx Pharmaceuticals
AMLX
$836M
| $49.2M | 1.64% | 2,688,873 -2,185,046 | -45% | -$40M |
|
19
BridgeBio Pharma
BBIO
$9.89B
| $46.1M | 1.54% | 1,748,933 | – | – |
|
20
Medtronic
MDT
$119B
| $46M | 1.53% | 587,000 +120,000 | +26% | +$9.4M |
|
21
Roivant Sciences
ROIV
$8.15B
| $44.6M | 1.49% | 3,819,456 +687,720 | +22% | +$8.03M |
|
22
Disc Medicine
IRON
$2.07B
| $42.1M | 1.4% | 895,641 +152,803 | +21% | +$7.18M |
|
23
Immatics
IMTX
$619M
| $40.4M | 1.35% | 3,491,500 | – | – |
|
|
24
Apogee Therapeutics
APGE
$2.17B
| $38.9M | 1.3% | +1,827,901 | New | +$38.9M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| $37.6M | 1.25% | 1,263,732 -683,205 | -35% | -$20.3M |
|